Policy

GLP-1 drugs work better for women, yet most can't get them. Why?

Women lose more weight than men on GLP-1 drugs, but 80% of eligible adults live in countries where retail prices put treatment out of reach.

Breast cancer home injections: Convenient for patients, complex for insurers

Despite the clinical benefits of home-based breast cancer therapy, insurance policies frequently impede patient access to these convenient injection programs.

Air pollution: Why policies fail, and patients pay the price

Despite clear evidence linking air pollution to adverse health outcomes, effective implementation of protective policies remains a significant hurdle.

Rheumatology care: Is lower drug cost worth limited access?

A new CMS drug pricing rule could lead to unintended consequences for patients with rheumatic diseases, according to the American College of Rheumatology.

Dialysis costs: Medicare as primary payer could save $1 billion

The Medicare Secondary Payer Act modestly reduced federal dialysis spending, but only when private prices were less than 3.05 times Medicare rates.

How regulatory guidance on real-world evidence changed drug submissions

Regulatory bodies have refined their expectations for real-world evidence, pushing sponsors to integrate these data earlier and more strategically into drug development programs.

Real-world evidence: How regulators changed what sponsors submit

Regulatory guidance on real-world evidence has evolved, prompting sponsors to integrate diverse data sources into submissions for drug approvals and label expansions.

Italy's COVID-19 Victims Association: Why Their Lobbying Success Matters for Future Pandemic Accountability

Six years after the initial COVID-19 outbreak, an Italian victims' association has achieved significant lobbying success, pushing for greater accountability over pandemic mismanagement.

Why for-profit firms in social care erode clinical standards

Andy Burnham's call to remove for-profit firms from social care reflects a growing concern that profit motives compromise patient outcomes and system resilience.